Imipenem/Cilastatina Hikma

Imipenem/Cilastatin, the active ingredient in Imipenem/Cilastatin Hikma, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections in hospitalized adults and children when other antibiotics are ineffective.

GNH USA supplies Imipenem/Cilastatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections in the following settings: - Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens causing pyelonephritis and cystitis. - Complicated skin and soft‑tissue infections: treats deep tissue infections caused by multidrug‑resistant organisms. - Lower respiratory tract infections (community‑acquired and hospital‑acquired): resolves pneumonia caused by Gram‑negative and Gram‑positive bacteria. - Febrile neutropenia: provides empiric coverage for high‑risk neutropenic patients.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: mild transaminase increase. - Injection site pain: discomfort at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Stevens‑Johnson syndrome: rare mucocutaneous necrolysis. - Severe neutropenia: marked reduction in white blood cells. - Acute renal failure: abrupt loss of kidney function.

Before initiating therapy, consider the following precautions: - Renal function assessment: adjust dose in patients with impaired kidney function. - Allergy history: avoid in individuals with known carbapenem or beta‑lactam hypersensitivity. - Seizure risk: monitor patients with a history of epilepsy or CNS disorders. - Concomitant valproic acid: avoid due to reduced plasma levels and loss of seizure control. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at below 25°C: keep in the original container, protect from moisture and light.

Imipenem/Cilastatin may interact with several drugs: Major Interactions (Avoid): - Valproic acid: reduces valproate levels, increasing seizure risk. - Renal dehydropeptidase inhibitors: may increase imipenem toxicity. - Penicillins or other beta‑lactams: cross‑reactivity can trigger allergic reactions. - Probenecid: can raise imipenem plasma concentrations. - Monoamine oxidase inhibitors: not recommended due to unknown interaction risk.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance nephrotoxic potential. - CNS depressants: additive risk of seizures. - Anticoagulants (warfarin): monitor INR as imipenem may affect coagulation parameters.